Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 Antibodies in Solid Tumors

Cancer Research

Volumn 71, Issue 6, 2011, Pages 2250-2259

  Rudnick, Stephen I ^a   Lou, Jianlong ^b   Shaller, Calvin C ^a   Tang, Yong ^c   Klein Szanto, Andres J P ^a   Weiner, Louis M ^c   Marks, James D ^b   Adams, Gregory P ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN G; INDIUM 111; IODINE 125; MONOCLONAL ANTIBODY; TRASTUZUMAB;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CATABOLISM; CONTROLLED STUDY; DIMERIZATION; DISSOCIATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TARGETING; DRUG TUMOR LEVEL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; LIGAND BINDING; MOUSE; NONHUMAN; OVARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS, NEOPLASM; BINDING, COMPETITIVE; CELL LINE, TUMOR; ENDOCYTOSIS; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MICE; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; TIME FACTORS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 79952741743     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2277     Document Type: Article

References (28)

1. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res 1989;49:5656-63. (Pubitemid 19256448)
2. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31:1191-8. (Pubitemid 20213280)
3. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814s-9s.
4. Ackerman ME, Pawlowski D, Wittrup KD. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther 2008;7:2233-40.
5. Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 2007;48:995-9. (Pubitemid 46909929)
6. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 2008;14:2171-9. (Pubitemid 351551130)
7. Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 2009;24:155-61.
8. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 2001;61:4750-5. (Pubitemid 32691886)
9. Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, et al. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol 1996;255:28-43. (Pubitemid 26104182)
10. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996;263:551-67. (Pubitemid 26382075)
11. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF III, Houston LL, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006;12:1599-605.
12. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 2007;179:2815-23.
13. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998;58:485-90. (Pubitemid 28087411)
14. Adams GP, Denardo SJ, Amin A, Kroger LA, DeNardo GL, Helström I, Helström KE. Comparison of the pharmacokinetics in mice and the biological-activity of murine L6 and human-mouse chimeric Ch-L6 antibody. Antib Immunoconjug Radiopharm 1992;5:81-95.
15. Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, Mattes MJ. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 1992;52:835-42.
16. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60:1421-34.
17. Lammerts van Bueren JJ, Bleeker WK, Bogh HO, Houtkamp M, Schuurman J, van de Winkel JG, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006;66:7630-8. (Pubitemid 44289220)
18. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem 2003;278:23343-51. (Pubitemid 36830149)
19. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004;15:5268-82. (Pubitemid 39564723)
20. Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Pluckthun A. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem 2006;281:35186-201. (Pubitemid 46043248)
21. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB. Processing of antibody-radioisotope conjugates after binding to the surface of tumor-cells. Cancer 1994;73:787-93. (Pubitemid 24046632)
22. Press OW, Shan D, HowellClark J, Eary J, Appelbaum FR, Matthews D, et al. Comparative metabolismand retention of iodine-125, yttrium- 90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56:2123-9. (Pubitemid 26119913)
23. Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor-cells in-vitro-a comparison of 9 radiolabels. J Nucl Med 1994;35:899-908. (Pubitemid 24151232)
24. Langmuir VK, Mendonca HL, Woo DV. Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids. Cancer Res 1992;52:4728-34.
25. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy- Davidescu G, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010;70:1595-605.
26. Friedman M, Stahl S. Engineered affinity proteins for tumour-targeting applications. Biotechnol Appl Biochem 2009;53:1-29.
27. Zhang Y, Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res 2008; 14:7981-6.
28. Kelley RF, O'Connell MP, Carter P, Presta L, Eigenbrot C, Covarrubias M, et al. Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments. Biochemistry 1992;31:5434-41.